Sugi Predict

Sugi Predict / Targets / BCL2L2

BCL2L2

Bcl-2-like protein 2 · Q92843 · BCL2L2 on Sugi Atlas →

21,355 patent compounds predicted against BCL2L2, 17,613 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1112346 SCHEMBL1112346 0.60 9/20
SCHEMBL1112349 SCHEMBL1112349 0.60 9/20
SCHEMBL1111901 SCHEMBL1111901 0.70 8/20
SCHEMBL1111904 SCHEMBL1111904 0.70 8/20
SCHEMBL1111890 SCHEMBL1111890 0.69 8/20
SCHEMBL1111894 SCHEMBL1111894 0.69 8/20
SCHEMBL158040 SCHEMBL158040 0.73 7/20
SCHEMBL158041 SCHEMBL158041 0.73 7/20
SCHEMBL553976 SCHEMBL553976 0.55 7/20
SCHEMBL553977 SCHEMBL553977 0.55 7/20
SCHEMBL1111796 SCHEMBL1111796 0.45 7/20
SCHEMBL1112404 SCHEMBL1112404 0.74 6/20
SCHEMBL1112407 SCHEMBL1112407 0.74 6/20
SCHEMBL1111891 SCHEMBL1111891 0.72 6/20
SCHEMBL1111895 SCHEMBL1111895 0.72 6/20
SCHEMBL555322 SCHEMBL555322 0.68 6/20
SCHEMBL555323 SCHEMBL555323 0.68 6/20
SCHEMBL431063 SCHEMBL431063 0.57 6/20
SCHEMBL431064 SCHEMBL431064 0.57 6/20
SCHEMBL1111911 SCHEMBL1111911 1.00 5/20

Clinical trials — most relevant to BCL2L2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia PHASE3COMPLETED
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009) PHASE3UNKNOWN
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas PHASE2/PHASE3ACTIVE_NOT_RECRUITING
Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia PHASE3COMPLETED
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme PHASE2COMPLETED
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma PHASE2RECRUITING
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL PHASE2RECRUITING
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors PHASE1/PHASE2COMPLETED
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL PHASE2ACTIVE_NOT_RECRUITING
Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission PHASE2ACTIVE_NOT_RECRUITING
Combination Immunotherapy Targeting Melanoma PHASE1/PHASE2RECRUITING
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML PHASE2ACTIVE_NOT_RECRUITING
SPC2996 in Chronic Lymphocytic Leukaemia PHASE1/PHASE2COMPLETED
Ibrutinib + Venetoclax in Untreated WM PHASE2ACTIVE_NOT_RECRUITING
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia PHASE2COMPLETED
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia PHASE2ACTIVE_NOT_RECRUITING
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme PHASE1COMPLETED
Safe Accelerated Venetoclax Escalation in CLL PHASE1ACTIVE_NOT_RECRUITING
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN PHASE1ACTIVE_NOT_RECRUITING
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer PHASE1COMPLETED
Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases PHASE1COMPLETED
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. nanRECRUITING
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation nanCOMPLETED
The Effect of TRA-8 on Ovarian Cancer Tissue nanCOMPLETED
Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer nanCOMPLETED
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia nanCOMPLETED
Smoking Influence on Apoptosis in Periodontitis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a BCL2L2 binder may also engage these)

ProteinNameSimilarity
Q1RMX3 — 1.000 Q1RMX3 →
Q45T69 — 1.000 Q45T69 →
P70345 — 1.000 P70345 →
Q90ZN1 — 0.987 Q90ZN1 →
Q07816 — 0.983 Q07816 →
Q91828 — 0.983 Q91828 →
BAX Apoptosis regulator BAX 0.982 landscape →
Q90343 — 0.982 Q90343 →
O02703 — 0.979 O02703 →
Q07813 — 0.977 Q07813 →
Q91827 — 0.977 Q91827 →
O08734 — 0.977 O08734 →
Q63690 — 0.976 Q63690 →
BCL2L1 Bcl-2-like protein 1 0.975 landscape →
Q08DK0 — 0.974 Q08DK0 →
Q9H3Z7 — 0.974 Q9H3Z7 →
O77737 — 0.974 O77737 →
O75064 — 0.973 O75064 →
Q64373 — 0.973 Q64373 →
Q9CR25 — 0.973 Q9CR25 →
Q9BVI4 — 0.973 Q9BVI4 →
P10937 — 0.972 P10937 →
Q1JQC5 — 0.972 Q1JQC5 →
P53563 — 0.972 P53563 →
Q002B5 — 0.971 Q002B5 →
Q8VDP3 — 0.971 Q8VDP3 →
A0AVI4 — 0.971 A0AVI4 →
Q8TE68 — 0.971 Q8TE68 →
BCL2L10 Bcl-2-like protein 10 0.970 landscape →
Q3U0V2 — 0.970 Q3U0V2 →